Generic names starting with "V"

Patents whose numbers are in italics have been extended under 35 USC 156. Unless otherwise noted, all expiration dates include applicable Sec. 156 and pediatric (PED) extensions.


Varicella Zoster Immune Globulin (Human) (For Injection) (Intramuscular) Varizig
Drug Classes: Immunological Agents:Immunoglobulins == Immunological Agents:Vaccines
NDA Applicant: Kamada Ltd.      BLA No.: 125430  Prod. No.: 002 Rx (125IU) BLA No.: 125430  Prod. No.: 001 Disc (125IU)
ExclusivityExpirationExclusivity Description
Exclusivity Type: Orphan Drug ExclusivityDec 20, 2019Orphan Designation: Passive immunization for the treatment of exposed, susceptible individuals who are at risk of complications from varicella
Approved Labeled Indication: Post exposure prophylaxis of varicella in high risk individuals to reduce the severity of varicella

vestronidase alfa-vjbk (Injection) (Intravenous) Mepsevii
Drug Classes: recombinant human lysosomal beta glucuronidase
NDA Applicant: Ultragenyx Pharamceutical Inc.      BLA No.: 761047  Prod. No.: 001 Rx (10MG/5ML (2MG/ML))
ExclusivityExpirationExclusivity Description
Exclusivity Type: Orphan Drug ExclusivityNov 15, 2024Orphan Designation: Treatment of mucopolysaccharidosis VII (MPS VII, Sly Syndrome)
Approved Labeled Indication: Indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII (PMS VII, Sly syndrome).
Exclusivity Protected Indication: Indicated in pediatric and adult patients for the treatment of mucopolysaccharidosis VII (MPS VII, Sly Syndrome).

von Willebrand factor (Recombinant) (For Injection) (Intravenous) Vonvendi
Drug Classes: Blood Products and Modifiers:Blood Component Deficiency/ Replacement == human blood coagulation factor
NDA Applicant: Baxalta US Inc.      BLA No.: 125577  Prod. No.: 001 Rx (1300IU); 002 Rx (650IU)
ExclusivityExpirationExclusivity Description
Exclusivity Type: Orphan Drug ExclusivityDec 8, 2022Orphan Designation: Treatment of von Willebrand disease
Approved Labeled Indication: Indicated for on-demand treatment and control of bleeding episodes in adults (age 18 and older) diagnosed with von Willebrand disease (VWD)
Exclusivity Protected Indication: Indicated for on-demand treatment and control of bleeding episodes in adults diagnosed with von Willebrand disease (VWD)
Exclusivity Type: Orphan Drug ExclusivityApr 13, 2025Orphan Designation: Treatment of von Willebrand disease
Approved Labeled Indication: Indicated for use in adults (age 18 and older) diagnosed with von Willebrand disease (VWD) for perioperative management of bleeding
Exclusivity Protected Indication: Indicated for use in adults (age 18 and older) diagnosed with von Willebrand disease (VWD) for perioperative management of bleeding

Voretigene Neparvovec (Injection) (Intraocular) Luxturna
Drug Classes: adeno-associated virus vector-based gene therapy
NDA Applicant: Spark Therapeutics, Inc.      BLA No.: 125610  Prod. No.: 001 Rx (1.5X10 TO 11 ML)
ExclusivityExpirationExclusivity Description
Exclusivity Type: Orphan Drug ExclusivityDec 19, 2024Orphan Designation: Treatment of inherited retinal dystrophy due to biallelic RPE65 gene mutations
Approved Labeled Indication: an adeno-associated virus vector-based gene therapy indicated for the treatment of patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy. Patients must have viable retinal cells determined by a treating physician
Exclusivity Protected Indication: Treatment of patients with confirmed biallelic RPE65 mutation-associated retinal distrophy. Patients must have viable retinal cells determined by a treating physician.



Last edited: 15 November 2022
© 2001-2022 Bruce A. Pokras, All rights reserved worldwide